ASC Therapeutics Licenses Tech from Expression Therapeutics to Advance Gene Therapies
ASC Therapeutics has gotten exclusive rights to Expression Therapeutics‘ technology to develop liver-targeting hemophilia A gene therapies.
Articles by Patricia Inácio, PhD
New Hemophilia Database Tracks and Updates Patient Clinical Data in Real Time, Trio Health Announces
Trio Health has launched a novel database with real-time clinical data of patients with hemophilia which combines information from…
SB-525 Continues to Show Encouraging Results for Hemophilia A in Phase 1/2 Trial
Investigational gene therapy SB-525 is well-tolerated and leads to a dose-dependent increase in factor VIII (FVIII), according to interim results from…
New Biomarker May Help Predict Response to Preventive Treatment with Factor VIII, Study Shows
New evidence suggests that a parameter called FVIII-EC50 has potential as a new way to predict the response of an…
Hemophilia A Patients Report Benefits of Using FuseNGo Device, Study Shows
According to hemophilia A patients, FuseNGo, Pfizer‘s pre-filled syringe device used for both the treatment and prevention of…
Discovery of Hemophilia A Subgroups May Help Predict FVIII Inhibitor Development
Researchers have identified four distinct subgroups of hemophilia A patients according to their profile of factor VIII-targeting antibodies. This may…
Hemlibra Now Available to Patients in Developing Countries via Aid Program
Hemlibra (emicizumab), the sole approved prophylactic treatment for hemophilia A, is now available to patients in developing countries via the…
Hemophilia Patients Show Worse Oral Hygiene than Healthy Controls, Study Reports
Oral hygiene among children and adults with severe hemophilia is poorer than in healthy controls, a single-center study suggests.
New Analysis Confirms Hemlibra’s Sustained Efficacy in Controlling Bleeding in Some Children With Hemophilia A
A new analysis of the Phase 3 HAVEN 2 study’s results shows that Genentech’s Hemlibra (emicizumab-kxwh) prophylaxis (preventive treatment) leads to…
FDA Approves Bayer’s Jivi for Hemophilia A Patients 12 and Older
The U.S. Food and Drug Administration has approved Bayer’s Jivi, previously known as BAY94-9027, as a preventive therapy for…